Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XB371 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose-escalation Cohorts | EXPERIMENTAL | Participants will receive escalating doses of XB371 every 3 weeks of a 21-day cycle (alternate schedules may be evaluated) until meeting the criteria for treatment discontinuation. |
| Dose-expansion Cohorts: Part A | EXPERIMENTAL | Participants with Tumor Type 1 (tumor type will be selected based on available data) will be randomized to receive XB371 at one of two recommended dose levels (recommended dose \[RD\]-1 or RD-2) every 3 weeks of a 21-day cycle (alternate schedules may be evaluated) until meeting the criteria for treatment discontinuation. |
| Dose-expansion Cohorts: Part B | EXPERIMENTAL | Participants with Tumor Type 2 (tumor type will be selected based on available data) will receive XB371 at the recommended dose level every 3 weeks of a 21-day cycle (alternate schedules may be evaluated) until meeting the criteria for treatment discontinuation. |
| Name | Type | Description |
|---|---|---|
| XB371 | DRUG | Intravenous (IV) infusion. |
Key Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. * Minimum life expectancy of ≥ 12 weeks. * Recurrent locally advanced or metastatic solid tumors. * Adequate end organ and bone marrow function. Key Exclusion Criteria: * Primary brain tumors or know...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
XB371 is an investigational small molecule being studied for the treatment of locally advanced or metastatic solid tumors. It is currently in Phase 1 clinical development, and its safety and efficacy have not yet been established.
XB371 targets TF, a protein involved in tumor biology. By targeting this protein, the drug aims to interfere with pathways that may contribute to tumor growth and progression, though its exact mechanism is still under investigation.
XB371 is being developed by Exelixis, Inc., a biopharmaceutical company. The company is conducting a Phase 1 clinical trial to evaluate the drug in patients with solid tumors.
XB371 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being tested for safety and efficacy in clinical trials.
XB371 is being studied in a Phase 1 clinical trial with the identifier NCT07123103. This trial is recruiting participants with locally advanced or metastatic solid tumors and is being conducted in the United States.